Search results
2 days ago · HER2 is a targetable molecular driver in mGC, and several therapies have been developed that target this pathway [[45], [46], [47]]. For example, trastuzumab (TRA), trastuzumab deruxtecan (T-DXd), trastuzumab emtansine (T-DM1), lapatinib (LAP), and pertuzumab are targeted therapies that inhibit HER2 receptor and downstream signaling pathways, thereby reducing tumor growth and enhancing survival outcomes (Fig. 2) [48].
1 day ago · Background Breast cancer (BC) is a heterogeneous neoplasm characterized by several subtypes. One of the most aggressive with high metastasis rates presents overexpression of the human epidermal growth factor receptor 2 (HER2). A quantitative evaluation of HER2 levels is essential for a correct diagnosis, selection of the most appropriate therapeutic strategy and monitoring the response to therapy. Results In this paper, we propose the synergistic use of SERS and Raman technologies for the ...
2 days ago · As the role of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) expands for patients with metastatic HER2-positive breast cancer and novel antibody-drug conjugates (ADCs) enter the scene ...
2 days ago · Finally, we compared the protein structure of a gene when a subtype-specific AS event occurred with the protein structure of a gene when no subtype-specific AS event occurred using PyMOL (v.1.20 ...
5 days ago · Background and Objective Dual human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab combined with taxane-based chemotherapy (Cht) has been the standard first-line treatment for HER2-positive metastatic breast cancer (mBC) for years, due to the impressive results of the CLEOPATRA study. Real-world (RW) studies have become critical for assessing treatment effectiveness and safety in real-life circumstances. The aim of this study was to analyze the treatment ...
3 days ago · Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89 Zr-Trastuzumab PET/CT. J Nucl Med 2016 ;57(10):1523–1528. Medline Google Scholar
4 days ago · In this regard, nearly 60% of breast cancer patients are diagnosed with HER2-low expression, defined as HER2 1+ or HER2 2+ by immunohistochemistry (IHC) and no gene amplification at reflex molecular testing. 45 DESTINY-Breast04 proved that targeting low level of HER2 with T-DXd was a superior therapeutic approach to standard chemotherapy in patients with unresectable or metastatic HER2-low breast cancer after prior treatment in the metastatic setting. 46 Based on DESTINY-Breast04, T-DXd ...
